You are here
Home > NANOBIOTIX

Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology

NANOBIOTIX ANNOUNCES PUBLICATION OF PHASE III SOFT TISSUE SARCOMA DATA FOR FIRST-IN-CLASS NBTXR3 IN THE LANCET ONCOLOGY   Previously reported data from the registration study (Act.In.Sarc) in advanced Soft Tissue Sarcoma (STS) patients demonstrated a significant advantage in both pathological complete response (pCR) and rate of margin-negative resection (R0) for those treated with NBTXR3 activated by […]

Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology

NANOBIOTIX ANNOUNCES PUBLICATION OF PHASE III SOFT TISSUE SARCOMA DATA FOR FIRST-IN-CLASS NBTXR3 IN THE LANCET ONCOLOGY   Previously reported data from the registration study (Act.In.Sarc) in advanced Soft Tissue Sarcoma (STS) patients demonstrated a significant advantage in both pathological complete response (pCR) and rate of margin-negative resection (R0) for those treated with NBTXR3 activated by […]

Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval

NANOBIOTIX ANNOUNCES NEW ORGANIZATIONAL STRUCTURE AS THE COMPANY ENTERS ITS NEXT STAGE AFTER FIRST EUROPEAN MARKET APPROVAL Recently appointed Chief Medical Officer (CMO) Edwina Baskin-Bey, M.D., will join the Executive Board Anne-Juliette Hermant, M.A., will be appointed Chief People Officer (CPO) and will join the Executive Board Former CMO Elsa Borghi, M.D., will lead innovation […]

NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL

NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL Biopharmaceutical veteran Edwina Baskin-Bey, M.D., joins Nanobiotix as its new Chief Medical Officer (CMO) Dr. Baskin-Bey will leverage her expertise in medical strategy and late-stage clinical development to help accelerate the company’s strategic objectives Dr. Baskin-Bey succeeds Elsa Borghi, […]

Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare

NANOBIOTIX ANNOUNCES THE LAUNCH OF CURADIGM: A NEW NANOTECHNOLOGY PLATFORM FOR HEALTHCARE Curadigm opens new growth pathways for Nanobiotix beyond oncology, built on the success and know-how established through the development of NBTXR3 Curadigm will operate as a wholly-owned subsidiary of Nanobiotix and the platform will be further developed through multiple anticipated partnerships Curadigm “Nanoprimer” […]

Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval

NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL Hensify®(NBTXR3) received European market approval (CE mark) enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma Hensify®–a first-in-class radioenhancer–offers cancer patients an innovative treatment with a broadly applicable mechanism of action After positive phase II/III data, this approval […]

Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

Data presented at AACR Annual Meeting 2019 In vivo study conducted alone or in collaboration with The University of Texas MD Anderson Cancer Center demonstrated: NBTXR3 in combination with a PD-1 inhibitor enhanced an abscopal effect in both sensitive and PD-1-inhibitor-resistant lung cancer models NBTXR3 in combination with a PD-1 inhibitor showed significant reduction of metastatic […]

Top